Gilead Sciences Inc. has described new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors potentially useful for the treatment of cancer. 100% 10 mM HCl formulation suspension form of an exemplified compound (Ex 13 pg 135, claim 42) exhibited bioavailability (F) of 48% in beagle dog plasma at 30 mg (equiv.)/kg p.o.